Potent Antineoplastic Effects of Combined PI3Kα-MNK Inhibition in Medulloblastoma.
Animals
Antineoplastic Agents
/ pharmacology
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cerebellar Neoplasms
/ drug therapy
Class I Phosphatidylinositol 3-Kinases
/ antagonists & inhibitors
Copper-Transporting ATPases
/ antagonists & inhibitors
Female
Humans
Medulloblastoma
/ drug therapy
Mice
Mice, Nude
Neoplastic Stem Cells
/ drug effects
Signal Transduction
/ drug effects
Xenograft Model Antitumor Assays
/ methods
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
10
11
2018
revised:
15
01
2019
accepted:
01
03
2019
pubmed:
8
3
2019
medline:
2
5
2020
entrez:
8
3
2019
Statut:
ppublish
Résumé
Medulloblastoma is a highly malignant pediatric brain tumor associated with poor outcome. Developing treatments that target the cancer stem cell (CSC) population in medulloblastoma are important to prevent tumor relapse and induce long-lasting clinical responses. We utilized medulloblastoma neurospheres that display CSC characteristics and found activation of the PI3K/AKT pathway in sphere-forming cells. Of all class I
Identifiants
pubmed: 30842251
pii: 1541-7786.MCR-18-1193
doi: 10.1158/1541-7786.MCR-18-1193
pmc: PMC6548590
mid: NIHMS1523513
doi:
Substances chimiques
Antineoplastic Agents
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
ATP7A protein, human
EC 7.2.2.8
Copper-Transporting ATPases
EC 7.2.2.8
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1305-1315Subventions
Organisme : NCI NIH HHS
ID : R01 CA121192
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA077816
Pays : United States
Organisme : CSRD VA
ID : I01 CX000916
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009560
Pays : United States
Organisme : NIH HHS
ID : S10 OD011996
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA060553
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221747
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS102669
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS093079
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Growth Factors. 2006 Mar;24(1):21-44
pubmed: 16393692
Neuro Oncol. 2017 Jan;19(1):139-141
pubmed: 28031383
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Mol Neurobiol. 2013 Dec;48(3):533-43
pubmed: 23516101
Mol Cell Biol. 2004 Aug;24(15):6539-49
pubmed: 15254222
Nature. 2012 Aug 2;488(7409):49-56
pubmed: 22832581
J Biol Chem. 2004 Nov 12;279(46):48063-70
pubmed: 15328362
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):13984-90
pubmed: 20679220
Mol Cancer Res. 2016 Oct;14(10):984-993
pubmed: 27364770
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Nat Rev Cancer. 2015 Jan;15(1):7-24
pubmed: 25533673
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Sci Rep. 2018 Jan 19;8(1):1211
pubmed: 29352211
Oncotarget. 2014 Sep 30;5(18):8442-51
pubmed: 25193863
Cancer Discov. 2016 Oct;6(10):1134-1147
pubmed: 27604488
Dis Model Mech. 2015 Jan;8(1):45-56
pubmed: 25431423
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Biotechniques. 2016 Jan 01;60(1):43-6
pubmed: 26757811
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E699-708
pubmed: 21876152
Genes Dev. 2008 Feb 15;22(4):436-48
pubmed: 18281460
Cell Stem Cell. 2011 May 6;8(5):486-98
pubmed: 21549325
Biochem J. 2007 Apr 15;403(2):217-34
pubmed: 17376031
Cell Signal. 2016 Sep;28(9):1412-21
pubmed: 27289018
Nat Rev Cancer. 2013 Oct;13(10):727-38
pubmed: 24060864
Clin Cancer Res. 2008 Nov 1;14(21):6761-9
pubmed: 18980969
Neuro Oncol. 2016 Nov;18(11):1519-1528
pubmed: 27370397
Neuro Oncol. 2015 Aug;17(8):1051-63
pubmed: 25934816
Expert Opin Ther Pat. 2013 Jul;23(7):789-99
pubmed: 23488930
Cancer Sci. 2016 May;107(5):583-9
pubmed: 27171351
Neuro Oncol. 2017 Oct 19;19(11):1469-1480
pubmed: 28379424
Nat Neurosci. 2015 Sep;18(9):1236-46
pubmed: 26258683
Clin Cancer Res. 2006 May 15;12(10):3019-27
pubmed: 16707597
Stem Cells. 2010 Nov;28(11):1930-9
pubmed: 20857497
Cancer Cell. 2014 Jul 14;26(1):136-49
pubmed: 25002028
PLoS One. 2015 Apr 27;10(4):e0123958
pubmed: 25915540
Cell. 2015 Jul 2;162(1):59-71
pubmed: 26095252
Cancer Res. 2012 Jul 1;72(13):3350-9
pubmed: 22573716
J Clin Oncol. 2018 May 1;36(13):1291-1299
pubmed: 29401002
Annu Rev Cell Dev Biol. 2001;17:615-75
pubmed: 11687500
PLoS One. 2013 May 24;8(5):e63748
pubmed: 23717474
Mol Cancer Res. 2018 Jan;16(1):32-46
pubmed: 29042487
Stem Cell Rev. 2008 Sep;4(3):203-10
pubmed: 18595010
Medicine (Baltimore). 2016 Sep;95(1 Suppl 1):S8-S19
pubmed: 27611937
Crit Rev Oncol Hematol. 2016 Sep;105:35-51
pubmed: 27375228
Oncotarget. 2016 May 31;7(22):33192-201
pubmed: 27120806
Nat Rev Drug Discov. 2014 Feb;13(2):140-56
pubmed: 24481312
Sci Transl Med. 2013 Jul 31;5(196):196ra99
pubmed: 23903756
Mol Cancer Ther. 2007 Mar;6(3):1167-74
pubmed: 17363510
Nat Genet. 2000 May;25(1):55-7
pubmed: 10802656